Skip to main content
NCBI home page
African Health Sciences logoLink to African Health Sciences
. 2023 Mar;23(1):614–621. doi: 10.4314/ahs.v23i1.65

Ginger supplementation for the treatment of non-alcoholic fatty liver disease: a meta-analysis of randomized controlled trials

Qun Zhou 1, Ying Peng 2, Fangyuan Chen 2, Jianbo Dai 3
PMCID: PMC10398503  PMID: 37545930

Abstract

Introduction

The efficacy of ginger supplementation remains controversial for non-alcoholic fatty liver disease. We conduct this meta-analysis to explore the influence of ginger supplementation versus placebo on the treatment of non-alcoholic fatty liver disease.

Methods

We have searched PubMed, EMbase, Web of science, EBSCO, and Cochrane library databases through November 2021 and included randomized controlled trials (RCTs) assessing the efficacy of ginger supplementation versus placebo for non-alcoholic fatty liver disease. This meta-analysis was performed using the random-effect model.

Results

Four RCTs involving 177 patients were included in the meta-analysis. Overall, compared with non-alcoholic fatty liver disease, ginger supplementation was associated with significantly reduced alanine aminotransferase (ALT, standard mean difference (SMD)=-0.43; 95% confidence interval [CI]=-0.85 to -0.02; P=0.04), homeostatic Model Assessment of Insulin Resistance (HOMA-IR, SMD=-1.14; 95% CI=-2.05 to -0.22; P=0.02), but revealed no obvious impact on aspartate-aminotransferase (AST, SMD=-0.66; 95% CI=-0.81 to 2.12; P=0.38), total cholesterol (SMD=-0.33; 95% CI=-0.67 to 0.02; P=0.06), low density lipoprotein (LDL, SMD=-0.30; 95% CI=-0.64 to 0.04; P=0.08) or body mass index (BMI, SMD=0; 95% CI=-0.41 to 0.40; P=0.99).

Conclusions

Ginger supplementation benefits to treat non-alcoholic fatty liver disease.

Keywords: ginger, non-alcoholic fatty liver disease, randomized controlled trials, meta-analysis

Introduction

Non-alcoholic fatty liver disease was identified by Ludwig in 1980 and accumulation of more than 5% triglyceride in hepatic parenchyma without notable alcohol consumption is defined as non-alcoholic fatty liver disease, which has become one global public health problem1–4. This disease is featured by a wide range of liver disorders from hepatocellular steatosis to more severe non-alcoholic steatohepatitis, which may progress to hepatic fibrosis and cirrhosis5–7.

There is still lack of effective treatment for non-alcoholic fatty liver disease, and new therapeutic approaches should be developed to improve the treatment efficacy8. Diets containing antioxidants and anti-inflammatory agents showed some benefits in the treating of non-alcoholic fatty liver disease9–11. Ginger was widely used worldwide as a spice, and demonstrated some efficacy to treat neurological diseases, diabetes, rheumatism, gingivitis, toothache, asthma, constipation, maldigestion, nausea and vomiting because of its roles in immune regulator, tumor inhibition, anti-inflammation, anti-apoptotic and antiemetic effects. There have been more than 40 antioxidant compounds that are identified in ginger12. Ginger family was reported to suppress nuclear factor-kappa B (NF-κB), which was the key protein complex for cytokine production and cellular responses to stimuli such as inflammatory cytokines and oxidative stress13–15.

In patients with non-alcoholic fatty liver disease, ginger supplement resulted in significant improvement in alanine aminotransferase (ALT), total cholesterol, low-density lipoprotein (LDL) and insulin resistance index (HOMA) compared to placebo 16. However, the benefit of ginger supplementation for non-alcoholic fatty liver disease has not been well established. Recently, several studies on the topic have been published, and the results were conflicting16–18. With accumulating evidence, we therefore searched for eligible randomized controlled trials (RCTs) assessing the efficacy of ginger supplementation versus placebo for non-alcoholic fatty liver disease and perform this meta-analysis using the random-effect model. Sensitivity analysis was also conducted. These aimed to explore the efficacy of ginger supplementation versus placebo for non-alcoholic fatty liver disease.

Materials and methods

Ethical approval and patient consent were not required because this was a meta-analysis of previously published studies. This meta-analysis was conducted and reported in adherence to PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) 19, 20.

Search strategy and study selection

Two investigators have independently searched the following databases (inception to November 2021): PubMed, EMbase, Web of science, EBSCO and Cochrane library databases. The electronic search strategy was conducted using the following keywords: “non-alcoholic fatty liver disease” OR “steatohepatitis” AND “ginger”. The inclusive selection criteria were as follows: (i) patients were diagnosed with non-alcoholic fatty liver disease; (ii) intervention treatments were ginger supplementation versus placebo; (iii) study design was RCT.

Data extraction and outcome measures

We extracted the following information: author, number of patients, age, female, weight, body mass index and detail methods in each group etc. Data were extracted independently by two investigators, and discrepancies were resolved by consensus. The primary outcomes were alanine aminotransferase (ALT) and aspartate-aminotransferase (AST). Secondary outcomes included homeostatic Model Assessment of Insulin Resistance (HOMA-IR), total cholesterol, low density lipoprotein (LDL) and body mass index (BMI).

Quality assessment in individual studies

Methodological quality of the included studies was independently evaluated using the modified Jadad scale 20,21. There were three items for Jadad scale: randomization (0-2 points), blinding (0-2 points), dropouts and withdrawals (0-1 points). The score of Jadad Scale varied from 0 to 5 points. An article with Jadad score≤2 had low quality. If the Jadad score≥3, the study was thought to have high quality 22, 23.

Statistical analysis

We estimated the standard mean difference (SMD) with 95% confidence interval (CI) for continuous outcomes. The random-effects model was used regardless of heterogeneity. Heterogeneity was reported using the I2 statistic, and I2 > 50% indicated significant heterogeneity24. Whenever significant heterogeneity was present, we searched for potential sources of heterogeneity via omitting one study in turn for the meta-analysis or performing subgroup analysis. All statistical analyses were performed using Review Manager Version 5.3 (The Cochrane Collaboration, Software Update, Oxford, UK).

Results

Literature search, study characteristics and quality assessment

A detailed flowchart of the search and selection results was presented in Figure 1. 184 potentially relevant articles were identified initially and four RCTs were finally included in the meta-analysis 16–18, 25. The baseline characteristics of four eligible RCTs were summarized in Table 1. The four studies were published between 2016 and 2020, and total sample size was 177. The doses of ginger supplementation ranged from 1000 mg daily to 1500 mg daily. Two studies reported the same patient sample with different outcomes. Among the four studies included here, three studies reported ALT and AST 16, 18, 25, three studies reported HOMA-IR 16, 17, 25, two studies reported total cholesterol and LDL 16, 17 and two studies reported BMI16,18. Jadad scores of the four included studies varied from 3 to 4, and all four studies had high quality.

Figure 1.

Figure 1

Open in a new tab

Flow diagram of study searching and selection process.

Table 1.

Characteristics of included studies

NO. Author,
year		 Ginger group Control group Jada
scores
Number Age
(years)		 Female
(n)		 Weight
(kg)		 Body
mass
index
(kg/m2)		 Methods Number Age
(years)		 Female
(n)		 Weight
(kg)		 Body
mass
index
(kg/m2)		 Methods
1 Rafie
2020		 23 50.04 ±
10.26		 13 - 31.70±3.75 1500
mg
ginger
powder
daily
for 12
weeks		 23 47.95
± 9.24		 13 - 30.94±1.98 placebo 4
2 Daneshi-Maskooni
2019		 43 45.5±8.9 16 85.2±11.3 30.5±2.4 two 500
mg
capsules
(green
cardamom
from
ginger
family)
three
times
per day
for 3
months		 44 45.0±7.7 17 88.6±13.2 30.7±3.2 placebo 4
3 Daneshi-Maskooni
2018		 43 45.5±8.9 16 85.2±11.3 30.5±2.4 two 500
mg
capsules
(green
cardamom
from
ginger
family)
three
times
per day
for 3
months		 44 45.0±7.7 17 88.6±13.2 30.7±3.2 placebo 4
4 Rahimlou
2016		 23 45.45±2.31 11 86.47±3.59 30.55±0.95 500 mg
ginger
capsules
twice
daily
for 12
weeks		 21 45±2.14 13 81.38±2.96 31.53±0.47 placebo 3
Open in a new tab

Primary outcomes: ALT and AST

These outcome data were analysed with the random-effects model, and compared to control group for non-alcoholic fatty liver disease, ginger supplementation was associated with significantly reduced ALT (SMD=-0.43; 95% CI=-0.85 to -0.02; P=0.04) with low heterogeneity among the studies (I2=44%, heterogeneity P=0.17, Figure 2), but showed no obvious influence on AST (SMD=-0.66; 95% CI=-0.81 to 2.12; P=0.38) with significant heterogeneity among the studies (I2=95%, heterogeneity P=0.38, Figure 3).

Figure 2.

Figure 2

Open in a new tab

Forest plot for the meta-analysis of ALT.

Figure 3.

Figure 3

Open in a new tab

Forest plot for the meta-analysis of AST.

Sensitivity analysis

Significant heterogeneity was observed among the included studies for the AST. As shown in Figure 3, the study conducted by Rahimlou showed the results that were almost out of range of the others and probably contributed to the heterogeneity 25. After excluding this study, the results suggested that ginger supplementation also demonstrated no significant impact on AST (SMD=-0.17; 95% CI=-0.56 to 0.21; P=0.37), and low heterogeneity remained (I2=19%, P=0.27).

Secondary outcomes

In comparison with control group for control group for non-alcoholic fatty liver disease, ginger supplementation substantially reduced HOMA-IR (SMD=-1.14; 95% CI=-2.05 to -0.22; P=0.02; Figure 4), but unravelled no obvious influence on total cholesterol (SMD=-0.33; 95% CI=-0.67 to 0.02; P=0.06; Figure 5), LDL (SMD=-0.30; 95% CI=-0.64 to 0.04; P=0.08; Figure 6) or BMI (SMD=0; 95% CI=-0.41 to 0.40; P=0.99; Figure 7).

Figure 4.

Figure 4

Open in a new tab

Forest plot for the meta-analysis of HOMA-IR

Figure 5.

Figure 5

Open in a new tab

Forest plot for the meta-analysis of total cholesterol.

Figure 6.

Figure 6

Open in a new tab

Forest plot for the meta-analysis of LDL.

Figure 7.

Figure 7

Open in a new tab

Forest plot for the meta-analysis of BMI.

Discussion

Inhibition of inflammatory and oxidative stress factors in patients with non-alcoholic fatty liver disease plays an important role in slowing the rate of progression and reducing the risk of cardiovascular disorders 26–28. Ginger has potential antioxidant activities due to its polyphenolic compounds as gingerol and curcumin, and thus inhibits lipid peroxidation 29. Our meta-analysis included four eligible RCTs and 177 patients, and the results confirmed that ginger supplementation exerted important beneficial effect on hepatic function and insulin resistance for non-alcoholic fatty liver disease, as evidenced by the significantly reduced ALT and HOMA-IR.

Two-hit hypothesis are widely accepted to cause non-alcoholic fatty liver disease. First hit is defined as insulin resistance that stimulates the synthesis of liver fatty acids and accumulation of fat in the liver and steatosis, and the liver is more susceptible to the second hit (i.e. oxidative stress from different sources) 16. Insulin resistance was substantially improved by ginger supplementation in our study. Insulin resistance, severe disorders of lipid metabolism, oxidative stress and inflammation play important roles in the pathogenesis of non-alcoholic fatty liver disease, and thus potential therapeutic agents are designed to target one or some of these pathological events. The fundamental role of insulin resistance is found in fat accumulation of liver, and the increase in insulin sensitivity is very promising against non-alcoholic fatty liver disease16, 30–32.

Several reasons may account for the beneficial effect of ginger supplementation on non-alcoholic fatty liver disease. Firstly, ginger has substantial ability to improve insulin sensitivity to adipocytes 33. Secondly, biosynthesis of cholesterol can be inhibited and more the transformation of cholesterol to bile acids is promoted by ginger treatment 34. Thirdly, ginger can inhibit arachidonic acid metabolism with the suppression of cyclooxygenase and lipoxygenase enzymes, thereby acting as an anti-inflammatory agent 16.

Regarding the sensitivity analysis, significant heterogeneity remained for AST. After excluding the study conducted by Rahimlou et al. 25, only low heterogeneity was found (I2=19%, P=0.27), and this heterogeneity was caused by the substantial difference in baseline AST 25. Our meta-analysis also has some importantt limitations. Firstly, our analysis is based on four RCTs, and all of them have a relatively small sample size (n<100). Overestimation of the treatment effect is more likely in smaller trials compared with larger samples. Secondly, although there is significant heterogeneity, different doses and forms of ginger supplementation may produce some bias. Thirdly, different etiologies and severity levels of non-alcoholic fatty liver disease may affect the efficacy assessment of ginger supplementation.

Conclusions

Ginger supplementation provides additional benefits to treat non-alcoholic fatty liver disease.

Acknowledgements

None.

Ethics approval and consent to participate

Not applicable.

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Funding

Not applicable.

References

  • 1.Younossi ZM. Non-alcoholic fatty liver disease - A global public health perspective. Journal of hepatology. 2019;70(3):531–544. doi: 10.1016/j.jhep.2018.10.033. [DOI] [PubMed] [Google Scholar]
  • 2.Vuppalanchi R, Chalasani N. Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis: Selected practical issues in their evaluation and management. Hepatology (Baltimore, Md.) 2009;49(1):306–317. doi: 10.1002/hep.22603. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 3.Neuschwander-Tetri BA. Non-alcoholic fatty liver disease. BMC medicine. 2017;15(1):45. doi: 10.1186/s12916-017-0806-8. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 4.Katsiki N, Mikhailidis DP, Mantzoros CS. Non-alcoholic fatty liver disease and dyslipidemia: An update, Metabolism. clinical and experimental. 2016;65(8):1109–1123. doi: 10.1016/j.metabol.2016.05.003. [DOI] [PubMed] [Google Scholar]
  • 5.Marchesini G, Bugianesi E, Forlani G, Cerrelli F, Lenzi M, Manini R, Natale S, Vanni E, Villanova N, Melchionda N, Rizzetto M. Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome. Hepatology (Baltimore, Md.) 2003;37(4):917–923. doi: 10.1053/jhep.2003.50161. [DOI] [PubMed] [Google Scholar]
  • 6.Bedossa P. Pathology of non-alcoholic fatty liver disease. Liver international :official journal of the International Association for the Study of the Liver. 2017;37(Suppl 1):85–89. doi: 10.1111/liv.13301. [DOI] [PubMed] [Google Scholar]
  • 7.Vilar-Gomez E, Chalasani N. Non-invasive assessment of non-alcoholic fatty liver disease: Clinical prediction rules and blood-based biomarkers. Journal of hepatology. 2018;68(2):305–315. doi: 10.1016/j.jhep.2017.11.013. [DOI] [PubMed] [Google Scholar]
  • 8.Singh S, Osna NA, Kharbanda KK. Treatment options for alcoholic and non-alcoholic fatty liver disease: A review. World journal of gastroenterology. 2017;23(36):6549–6570. doi: 10.3748/wjg.v23.i36.6549. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 9.Chen H, Huang W, Huang X, Liang S, Gecceh E, H OS, Khani V, Jiang X. Effects of green coffee bean extract on C-reactive protein levels: A systematic review and meta-analysis of randomized controlled trials. Complementary therapies in medicine. 2020;52:102498. doi: 10.1016/j.ctim.2020.102498. [DOI] [PubMed] [Google Scholar]
  • 10.Abbasnezhad A, Choghakhori R, Kashkooli S, Alipour M, Asbaghi O, Mohammadi R. Effect of L-carnitine on liver enzymes and biochemical factors in hepatic encephalopathy: A systematic review and meta-analysis. Journal of gastroenterology and hepatology. 2019;34(12):2062–2070. doi: 10.1111/jgh.14765. [DOI] [PubMed] [Google Scholar]
  • 11.Mahdavinia M, Alizadeh S, Raesi A, Vanani, Dehghani MA, Shirani M, Alipour M, Shahmohammadi HA, Rafiei Asl S. Effects of quercetin on bisphenol A-induced mitochondrial toxicity in rat liver. Iranian journal of basic medical sciences. 2019;22(5):499–505. doi: 10.22038/ijbms.2019.32486.7952. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 12.Ali BH, Blunden G, Tanira MO, Nemmar A. Some phytochemical, pharmacological and toxicological properties of ginger (Zingiber officinale Roscoe): a review of recent research. Food and chemical toxicology: an international journal published for the British Industrial Biological Research Association. 2008;46(2):409–420. doi: 10.1016/j.fct.2007.09.085. [DOI] [PubMed] [Google Scholar]
  • 13.Gilmore TD. Introduction to NF-kappaB: players, pathways, perspectives. Oncogene. 2006;25(51):6680–6684. doi: 10.1038/sj.onc.1209954. [DOI] [PubMed] [Google Scholar]
  • 14.Brglez Mojzer E, Knez Hrnčič M, Škerget M, Knez Ž, Bren U. Polyphenols: Extraction Methods, Antioxidative Action, Bioavailability and Anticarcinogenic Effects, Molecules (Basel, Switzerland) 2016;21(7) doi: 10.3390/molecules21070901. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 15.Hämäläinen M, Nieminen R, Vuorela P, Heinonen M, Moilanen E. Anti-inflammatory effects of flavonoids: genistein, kaempferol, quercetin, and daidzein inhibit STAT-1 and NF-kappaB activations, whereas flavone, isorhamnetin, naringenin, and pelargonidin inhibit only NF-kappaB activation along with their inhibitory effect on iNOS expression and NO production in activated macrophages. Mediators of inflammation. 2007;2007:45673. doi: 10.1155/2007/45673. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 16.Rafie R, Hosseini SA, Hajiani E, Saki Malehi A, Mard SA. Effect of Ginger Powder Supplementation in Patients with Non-Alcoholic. Fatty Liver Disease: A Randomized Clinical Trial, Clinical and experimental gastroenterology. 2020;13:35–45. doi: 10.2147/CEG.S234698. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 17.Daneshi-Maskooni M, Keshavarz SA, Qorbani M, Mansouri S, Alavian SM, Badri-Fariman M, Jazayeri-Tehrani SA, Sotoudeh G. Green cardamom supplementation improves serum irisin, glucose indices, and lipid profiles in overweight or obese non-alcoholic fatty liver disease patients: a double-blind randomized placebo-controlled clinical trial. BMC complementary and alternative medicine. 2019;19(1):59. doi: 10.1186/s12906-019-2465-0. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 18.Daneshi-Maskooni M, Keshavarz SA, Qorbani M, Mansouri S, Alavian SM, Badri-Fariman M, Jazayeri-Tehrani SA, Sotoudeh G. Green cardamom increases Sirtuin-1 and reduces inflammation in overweight or obese patients with non-alcoholic fatty liver disease: a double-blind randomized placebo-controlled clinical trial. Nutrition & metabolism. 2018;15:63. doi: 10.1186/s12986-018-0297-4. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 19.Moher D, Liberati A, Tetzlaff J, Altman DG, P. Group Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Journal of clinical epidemiology. 2009;62(10):1006–1012. doi: 10.1016/j.jclinepi.2009.06.005. [DOI] [PubMed] [Google Scholar]
  • 20.He B, Zhao J-Q, Zhang M-Z, Quan Z-X. Zoledronic acid and fracture risk: a meta-analysis of 12 randomized controlled trials. Eur Rev Med Pharmacol Sci. 2021;25:1564–1573. doi: 10.26355/eurrev_202102_24865. [DOI] [PubMed] [Google Scholar]
  • 21.Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJM, Gavaghan DJ, McQuay HJ. Assessing the quality of reports of randomized clinical trials: Is blinding necessary? Controlled Clinical Trials. 1996;17(1):1–12. doi: 10.1016/0197-2456(95)00134-4. [DOI] [PubMed] [Google Scholar]
  • 22.Kjaergard LL, Villumsen J, Gluud C. Reported Methodologic Quality and Discrepancies between Large and Small Randomized Trials in Meta-Analyses. Annals of Internal Medicine. 2001;135(11):982–989. doi: 10.7326/0003-4819-135-11-200112040-00010. [DOI] [PubMed] [Google Scholar]
  • 23.Zhao J, Huang W, Zhang S, Xu J, Xue W, He B, Zhang Y. Efficacy of Glutathione for Patients with Cystic Fibrosis: A Meta-analysis of Randomized-Controlled Studies. Am J Rhinol Allergy. 2020;34(1):115–121. doi: 10.1177/1945892419878315. [DOI] [PubMed] [Google Scholar]
  • 24.Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Statistics in medicine. 2002;21(11):1539–1558. doi: 10.1002/sim.1186. [DOI] [PubMed] [Google Scholar]
  • 25.Rahimlou M, Yari Z, Hekmatdoost A, Alavian SM, Keshavarz SA. Ginger Supplementation in Nonalcoholic Fatty Liver Disease: A Randomized, Double-Blind, Placebo-Controlled Pilot Study. Hepatitis monthly. 2016;16(1):e34897. doi: 10.5812/hepatmon.34897. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 26.Mukhopadhyay P, Horváth B, Rajesh M, Varga ZV, Gariani K, Ryu D, Cao Z, Holovac E, Park O, Zhou Z, Xu MJ, Wang W, Godlewski G, Paloczi J, Nemeth BT, Persidsky Y, Liaudet L, Haskó G, Bai P, Boulares AH, Auwerx J, Gao B, Pacher P. PARP inhibition protects against alcoholic and non-alcoholic steatohepatitis. Journal of hepatology. 2017;66(3):589–600. doi: 10.1016/j.jhep.2016.10.023. [DOI] [PubMed] [Google Scholar]
  • 27.Hwangbo H, Kim MY, Ji SY, Kim SY, Lee H, Kim GY, Park C, Keum YS, Hong SH, Cheong J, Choi YH. Auranofin Attenuates Non-Alcoholic Fatty Liver Disease by Suppressing Lipid Accumulation and NLRP3 Inflammasome-Mediated Hepatic Inflammation In Vivo and In Vitro. Antioxidants (Basel, Switzerland) 2020;9(11) doi: 10.3390/antiox9111040. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 28.Shen B, Zhao C, Wang Y, Peng Y, Cheng J, Li Z, Wu L, Jin M, Feng H. Aucubin inhibited lipid accumulation and oxidative stress via Nrf2/HO-1 and AMPK signalling pathways. Journal of cellular and molecular medicine. 2019;23(6):4063–4075. doi: 10.1111/jcmm.14293. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 29.Stoilova I, Krastanov A, Stoyanova A, Denev P, Gargova S. Antioxidant activity of a ginger extract (Zingiber officinale) Food Chemistry. 2007;10(3):764–770. [Google Scholar]
  • 30.Spahis S, Alvarez F, Ahmed N, Dubois J, Jalbout R, Paganelli M, Grzywacz K, Delvin E, Peretti N, Levy E. Non-alcoholic fatty liver disease severity and metabolic complications in obese children: impact of omega-3 fatty acids. The Journal of nutritional biochemistry. 2018;58:28–36. doi: 10.1016/j.jnutbio.2018.03.025. [DOI] [PubMed] [Google Scholar]
  • 31.Arroyave-Ospina JC, Wu Z, Geng Y, Moshage H. Role of Oxidative Stress in the Pathogenesis of Non-Alcoholic Fatty Liver Disease: Implications for Prevention and Therapy. Antioxidants (Basel, Switzerland) 2021;10(2) doi: 10.3390/antiox10020174. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 32.Farzanegi P, Dana A, Ebrahimpoor Z, Asadi M, Azarbayjani MA. Mechanisms of beneficial effects of exercise training on non-alcoholic fatty liver disease (NAFLD): Roles of oxidative stress and inflammation. European journal of sport science. 2019;19(7):994–1003. doi: 10.1080/17461391.2019.1571114. [DOI] [PubMed] [Google Scholar]
  • 33.Sahebkar A. Potential efficacy of ginger as a natural supplement for nonalcoholic fatty liver disease. World journal of gastroenterology. 2011;17(2):271–272. doi: 10.3748/wjg.v17.i2.271. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 34.Verma SK, Singh M, Jain P, Bordia A. Protective effect of ginger, Zingiber officinale Rosc on experimental atherosclerosis in rabbits. Indian journal of experimental biology. 2004;42(7):736–738. [PubMed] [Google Scholar]

Articles from African Health Sciences are provided here courtesy of Makerere University Medical School

RESOURCES